Trial Profile
A retrospective study assessing the efficacy and safety of anlotinib in switch maintenance after chemotherapy in patients with unresectable or metastatic Soft tissue sarcoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Sep 2020
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Gemcitabine; Ifosfamide; Mesna
- Indications Chordoma; Leiomyosarcoma; Sarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 30 Sep 2020 New trial record
- 24 Sep 2020 Results published in the Investigational New Drugs